develop
genet
engin
techniqu
speed
growth
biotechnolog
industri
result
signific
increas
number
recombin
protein
product
market
deep
knowledg
protein
function
structur
biolog
interact
possibl
design
new
polypeptid
desir
biolog
activ
main
factor
involv
increas
intens
research
preclin
clinic
approach
consequ
new
biolog
entiti
ad
valu
innov
medicin
increas
stabil
improv
target
reduc
toxic
among
other
obtain
protein
complex
nanoparticl
size
rang
nanomet
hundr
nanomet
complex
supramolecular
interact
occur
exampl
viral
capsid
howev
even
though
protein
product
delic
process
impos
use
sophist
analyt
method
neg
secondari
effect
detect
case
immun
inflammatori
reaction
great
potenti
biodegrad
tunabl
protein
nanoparticl
indic
proteinbas
biotechnolog
product
expect
increas
year
come
design
new
chemic
entiti
nce
diagnosi
treatment
human
diseas
reli
discoveri
activ
chemic
drug
divers
librari
compound
natur
occur
molecul
chemic
modif
improv
pharmacokinet
properti
obtain
final
product
known
mechan
action
decreas
toxic
nonetheless
use
approach
final
product
present
low
specif
target
molecul
interact
mani
molecul
accumul
tissu
disturb
correct
homeostasi
system
case
advers
effect
drug
administr
exceed
pharmacolog
effect
despit
concis
mechan
action
drug
target
molecul
repres
improv
patient
state
treatment
prevent
discontinu
fact
although
maintain
steadi
increas
number
launch
nce
observ
last
year
question
aris
whether
classic
approach
alreadi
exhaust
discoveri
innov
molecul
hand
macromolecular
new
biolog
entiti
nbe
use
supplement
cellular
defici
inhibit
cellular
pathway
exploit
rel
specif
mode
action
protein
peptid
obtain
first
natur
sourc
produc
recombin
version
develop
genet
engin
techniqu
late
howev
deliveri
biolog
entiti
sometim
hamper
low
halflif
bloodstream
unspecif
degrad
result
expens
ineffect
process
nevertheless
solut
alreadi
explor
biopharmaceut
increas
solubl
stabil
reduc
immunogen
includ
postransl
modif
glycosyl
coval
conjug
polyethylen
glycol
thu
one
main
object
use
drug
either
nce
nbe
need
optim
deliveri
system
reduc
pharmacolog
dose
would
consequ
repres
concomit
reduct
toxic
cost
scenario
new
deliveri
approach
implement
use
biolog
interact
antigenantibodi
bind
immunoliposom
sophist
interact
includ
bind
nutrient
concentr
sparc
secret
protein
acid
rich
cystein
albumin
treatment
type
cancer
abraxan
protein
use
target
qualiti
molecular
deliveri
vehicl
specif
deliveri
drug
nucleic
acid
gene
therapi
approach
therapeut
molecul
one
interest
characterist
protein
abil
form
intermolecular
driven
complex
sophist
structur
perfect
case
viral
capsid
addit
use
genet
engin
recombin
protein
tune
includ
addit
properti
optim
drug
deliveri
nucleic
acid
deliveri
gene
therapi
chapter
main
avail
strategi
develop
proteinbas
nanovehicl
biopharmaceut
describ
context
sever
paramet
defin
proper
formul
stabil
immunogen
deliveri
correct
cell
type
cell
compart
modular
protein
engin
viruslik
particl
vlp
selfassembl
entiti
envis
modulat
novel
protein
nanoparticl
abl
includ
mani
desir
properti
correct
deliveri
drug
nucleic
acid
final
success
exampl
protein
nanoparticl
market
describ
addit
protein
product
current
clinic
trial
preclin
research
order
envis
type
protein
nanoparticl
avail
soon
market
therapeut
molecul
gener
vehicl
capabl
transport
blood
system
administr
need
retain
signific
stabil
reach
target
cell
addit
biolog
system
pose
specif
barrier
overcom
membran
cytoplasm
endocyt
nuclear
degrad
proteas
degrad
induc
acid
denatur
lysosom
cytosol
proteosom
nucleas
cytosol
transport
nuclear
entri
necessari
central
nervou
system
therapi
bloodbrain
barrier
bbb
repres
main
bottleneck
specif
strategi
design
furthermor
therapeut
complex
flexibl
enough
order
releas
therapeut
molecul
specif
cell
compart
thu
sever
protein
motif
describ
overcom
everi
process
describ
earlier
modular
multifunct
protein
gener
includ
modul
necessari
achiev
goal
order
get
ration
construct
multifunct
vector
step
care
taken
account
overcom
everi
step
need
achiev
final
goal
tabl
dnarna
condens
drug
interact
protein
vector
critic
step
formul
protein
nanoparticl
gene
therapi
remain
attach
vector
whole
transport
process
bodi
cell
releas
desir
local
within
target
cell
highli
posit
charg
peptid
contain
larg
number
arginin
polylysin
use
promot
electrostat
interact
sinc
nucleic
acid
highli
neg
charg
molecul
natur
dnacondens
protein
nuclear
histidin
protamin
also
use
bind
nucleic
acid
protamin
protein
replac
histidin
spermatogenesi
process
sperm
chromatin
compon
histidin
high
dna
condens
abil
protect
nucleic
acid
form
cytosol
endonucleas
addit
soon
complex
reach
cellular
nucleu
protamin
degrad
chromatinremodel
protein
releas
transport
dna
allow
express
contrast
polycation
dna
condens
modul
polylysin
polyarginineseven
present
higher
dna
condens
abil
depend
polycation
chain
lengthusu
present
lower
dnareleas
abil
interf
neg
access
cellular
transcript
factor
dna
express
capac
dna
condens
modul
describ
interact
dna
incub
unspecif
way
howev
protein
abl
recogn
specif
dna
sequenc
permit
bind
condens
specif
dna
sequenc
final
vector
mani
case
multifunct
protein
vector
vivo
administr
system
rout
order
travel
blood
reach
target
cell
expos
vector
blood
compon
make
suscept
degrad
thu
complet
necessari
vector
remain
blood
long
enough
abl
reach
target
cell
also
describ
nake
dna
estim
halflif
blood
minut
protein
nanovehicl
gene
therapi
among
properti
intend
protect
nucleic
acid
degrad
one
import
factor
vector
expos
blood
recogn
immun
system
compon
produc
immun
respons
vector
thu
also
import
tri
make
vector
less
antigen
possibl
order
avoid
degrad
even
toxic
organ
peptid
uptak
intern
involv
step
protein
bind
cell
surfac
attach
either
specif
unspecif
case
promot
intern
requir
posit
charg
peptid
usual
bind
cellular
surfac
unspecif
electrostat
interact
neg
charg
cell
surfac
proteoglican
kind
peptid
use
multifunct
protein
specif
target
requir
cellpenetr
peptid
cpp
wide
describ
unspecif
cellbind
intern
peptid
see
also
chapter
peptid
nanoparticl
oligonucleotid
deliveri
lehto
et
al
volum
howev
specif
interact
obtain
incorpor
cell
receptor
ligand
cell
tissu
target
requir
therapeut
action
moreov
ligandreceptor
interact
promot
ligandreceptor
complex
intern
mani
peptid
describ
literatur
receptorspecif
ligand
ad
multifunct
protein
order
confer
cell
specif
natur
specif
ligand
also
use
cell
target
monoclon
antibodi
addit
specif
peptid
avail
intend
target
new
specif
bind
peptid
found
use
phage
display
combinatori
chemistri
endosom
escap
sever
intern
pathway
possibl
depend
vector
properti
includ
endocytosi
clathrincaveolaemedi
clathrin
caveolaeindepend
macropinocytosi
nonendocyt
pathway
known
one
intern
pathway
perform
time
usual
peptidebas
vector
use
endocyt
pathway
moreov
seem
protein
interact
specif
cellular
receptor
intern
clathrinmedi
endocyt
pathway
gener
endosom
vesicl
converg
late
endosom
eventu
fuse
cellular
lysosom
remain
cellular
endosom
multifunct
protein
degrad
strictli
necessari
intern
multifunct
protein
releas
cellular
cytoplasm
escap
degrad
sever
peptid
describ
abl
promot
endosom
escap
classifi
two
type
depend
escap
mechan
fusiogen
peptid
histidinerich
peptid
fusiogen
peptid
small
peptid
hydrophob
amino
acid
aa
interspers
constant
interv
neg
charg
aa
thu
earli
endosom
becom
late
endosom
low
ph
induc
conform
chang
peptid
adopt
alphahelix
structur
amphipath
structur
abl
fuse
endosom
membran
lead
pore
format
releas
endosom
content
cell
cytoplasm
histidinerich
peptid
small
peptid
high
histidin
content
whose
endosmolyt
activ
mediat
mechan
call
proton
spong
endosom
ph
becom
low
late
stage
imidazol
group
histidin
proton
attract
endosom
cl
ion
buffer
proton
pump
thu
endosom
collaps
osmolyt
swell
process
endosom
content
releas
cell
cytoplasm
detail
given
chapter
peptid
nanoparticl
oligonucleotid
deliveri
lehto
et
al
volum
protein
achiev
cellular
cytosol
degrad
cellular
proteas
cellular
proteosom
system
import
avoid
process
especi
protein
reach
cellular
nucleu
final
target
nanoparticl
cellular
cytoplasm
necessari
remain
least
long
enough
perform
therapeut
action
sever
peptid
proteosom
inhibitor
describ
abl
avoid
type
protein
degrad
ad
peptid
final
protein
vector
possibl
protect
enhanc
cytoplasmat
stabil
epsteinbarr
viru
nuclear
antigen
contain
proteosom
inhibitor
consist
glycinealanin
repeat
abl
prevent
proteosom
proteolysi
shown
minimum
aa
glyala
repeat
necessari
achiev
protect
activ
protein
vector
carri
nucleic
acid
dna
rna
degrad
cytosol
endonucleas
taken
account
also
import
protect
nucleic
acid
order
maintain
integr
dnarna
condens
peptid
protamin
also
protect
dna
cytoplasm
endonucleas
enhanc
stabil
describ
cellular
cytoplasm
crowd
compartment
environ
cellular
organel
cytoskeleton
make
free
diffus
macromolecul
protein
vector
difficult
howev
cytoskeleton
element
microtubul
use
endosom
cytosol
macromolecul
intracytosol
mobil
dynein
describ
capabl
carri
macromolecul
endosom
along
microtubul
retrograd
transport
toward
nucleu
small
peptid
abl
bind
dynein
identifi
ad
multifunct
protein
vector
order
mediat
intracytosol
mobil
toward
cellular
nucleu
sever
dyneinbind
protein
identifi
virus
abl
use
transport
system
compar
protein
sequenc
consensu
peptid
sequenc
kstqt
abl
bind
dynein
light
chain
identifi
molecul
lower
nm
abl
enter
cellular
nucleu
passiv
diffus
howev
macromolecul
higher
kda
nm
gener
requir
activ
transport
system
nuclear
pore
system
transport
mechan
gener
requir
specif
target
signal
peptid
name
nuclear
local
signal
nl
signal
peptid
usual
rich
basic
aa
recogn
cellular
importin
activ
transport
nuclear
pore
monopartit
bipartit
nl
sequenc
nl
peptid
one
two
nl
recogn
sequenc
respect
describ
thu
peptid
sequenc
ad
final
multifunct
protein
nuclear
local
requir
order
express
carri
dna
report
singl
nl
sequenc
suffici
transport
vector
nucleu
larg
number
nl
sequenc
result
inhibit
activ
one
use
nl
signal
peptid
fragment
deriv
aa
simian
viru
larg
tumor
antigen
tag
nl
sequenc
found
protamin
tat
import
transport
dna
reach
cellular
nucleu
releas
order
access
nuclear
transcript
factor
achiev
desir
express
level
thu
design
multifunct
protein
vector
aspect
taken
account
dna
releas
cell
nucleu
necessari
control
express
level
depend
therapeut
action
promot
goal
kill
cell
cancer
therapi
uncontrol
dna
express
level
would
problem
howev
specif
protein
express
level
requir
achiev
good
control
import
express
system
develop
pharmacolog
regul
oral
drug
formul
cellspecif
promot
enhanc
also
use
order
confer
high
cell
specif
therapi
way
get
bbb
bbb
hermet
barrier
allow
nonlipophil
molecul
smaller
da
cross
howev
human
protein
insulin
transferrin
insulinlik
growth
factor
leptin
abl
go
across
receptormedi
transport
thu
import
factor
limit
central
nervou
systemtarget
therapeut
presenc
bbb
find
way
cross
main
challeng
peptid
describ
abl
reach
brain
cross
bbb
moreov
seen
associ
anoth
molecul
transport
barrier
thu
could
interest
candid
includ
multifunct
vector
central
nervou
system
target
requir
antibodi
also
describ
bind
transferrin
insulin
receptor
abl
cross
bbb
effici
conjug
larg
molecul
allow
transloc
central
nervou
system
synthesi
ration
design
develop
genet
engin
techniqu
increas
natur
repertoir
protein
design
use
andor
valuabl
protein
aim
obtain
new
protein
desir
function
three
main
strategi
lead
construct
engin
protein
direct
evolut
b
de
novo
protein
design
c
ration
design
direct
evolut
develop
quickli
becom
method
choic
protein
engin
order
creat
enzym
desir
properti
kind
process
past
decad
techniqu
becom
daili
part
molecular
toolbox
everi
biochemist
emphas
increas
number
public
subject
natur
evolut
creation
new
function
achiev
mutagenesi
recombin
surviv
fittest
direct
evolut
mimic
process
iter
cycl
produc
mutant
find
mutant
desir
properti
mutat
introduc
specif
place
use
sitedirect
mutagenesi
throughout
gene
random
mutagenesi
sever
mutagenesi
techniqu
develop
order
avoid
codon
bia
first
techniqu
use
mimic
evolut
dna
shuffl
method
base
mix
subsequ
join
differ
relat
small
dna
fragment
order
form
complet
new
gene
process
shuffl
recombin
frequenc
depend
degre
homolog
high
level
recombin
import
get
possibl
combin
mutat
sinc
recombin
bias
sever
method
overcom
problem
aris
use
shuffl
earli
year
tackl
novel
strategi
advantag
disadvantag
product
obtain
method
screen
desir
qualiti
easili
screen
de
novo
protein
design
offer
broadest
possibl
new
structur
base
search
amino
acid
sequenc
compat
threedimension
protein
backbon
templat
use
silico
techniqu
sever
research
group
field
appli
silico
method
design
hydrophob
core
protein
novel
sequenc
valid
experiment
data
silico
protein
design
allow
novel
function
templat
origin
lack
properti
modifi
exist
function
increas
protein
stabil
specif
beyond
doubt
intens
research
activ
ongo
field
potenti
simpli
enorm
far
numer
exampl
full
sequenc
design
scratch
confirm
fold
target
threedimension
structur
experiment
data
zincfing
protein
design
dahiyat
mayo
first
one
appear
method
ration
design
protein
base
modif
insert
select
amino
acid
domain
polypeptid
chain
backbon
obtain
protein
new
alter
biolog
function
use
strategi
detail
knowledg
structur
function
backbon
protein
need
make
desir
chang
gener
advantag
inexpens
technic
feasibl
howev
major
drawback
approach
detail
structur
knowledg
protein
often
unavail
extrem
difficult
predict
effect
variou
mutat
modular
engin
enabl
use
simpl
dna
recombin
techniqu
construct
chimer
polypeptid
select
domain
potenti
differ
origin
provid
requir
activ
equilibr
combin
spatial
distribut
partner
element
gener
promis
prototyp
abl
deliv
express
dna
molecul
tissu
cultur
also
specif
cell
type
whole
organ
modular
fusion
protein
combin
distinct
function
requir
cell
typespecif
uptak
intracellular
deliveri
dna
drug
present
attract
approach
develop
selfassembl
vector
target
gene
drug
deliveri
one
first
exampl
describ
group
uherek
et
al
combin
cellspecif
target
modul
antibodi
fragment
specif
tumorassoci
antigen
dnabind
domain
transloc
domain
endosom
escap
context
mani
strategi
construct
safer
vehicl
explor
number
nonvir
prototyp
vector
gene
drug
deliveri
notic
increas
common
step
approach
like
might
explor
present
fig
design
new
protein
drug
gene
deliveri
mani
critic
aspect
name
design
vehicl
requir
function
stabil
etc
b
product
protein
suitabl
express
system
purif
procedur
scale
process
etc
c
character
vehicl
physicochem
function
test
final
administr
rout
regulatori
guidanc
biolog
product
although
aspect
belong
differ
disciplin
overview
togeth
major
need
modular
protein
gene
drug
deliveri
present
enhanc
physicochem
stabil
cargo
molecul
resist
nucleaseproteasemedi
degrad
protein
vehicl
ideal
exhibit
like
natur
counterpart
virus
nucleicacid
bind
condens
properti
abil
gener
confer
cation
segment
main
scaffold
molecul
interact
nucleic
acid
mainli
electrostat
interact
addit
complex
need
effici
releas
nucleic
acid
nucleu
cargo
therapeut
gene
endosom
escap
requir
function
found
peptid
mani
natur
molecul
suitabl
function
protein
vehicl
abil
bind
particular
cell
type
high
specif
especi
signific
system
deliveri
appropri
biodistribut
tissu
target
essenti
nuclear
target
nake
short
nucleic
acid
freeli
enter
nucleu
nondivid
cell
via
free
diffus
nuclear
pore
larg
molecul
requir
activ
transport
mediat
nlss
often
found
viral
protein
molecular
mass
plasmid
dna
vari
mda
dna
express
essenti
macromolecular
complex
nucleic
acid
deliveri
requir
nlss
role
type
function
modul
peptid
use
purpos
discuss
depth
follow
section
vivo
experi
final
protein
peptid
better
given
cargo
determin
empir
rule
taken
liter
c
product
protein
nanoparticl
step
product
proteinbas
vehicl
molecular
clone
protein
product
protein
purif
might
experiment
labor
intens
variabl
success
rate
reason
small
protein
need
solidphas
peptid
synthesi
guarante
process
howev
classic
procedur
biolog
product
allow
scale
process
case
product
larger
polypeptid
fulllength
protein
gener
protein
nanoparticl
approach
protein
compos
differ
modul
natur
sourc
cellpenetr
peptid
transactiv
transcript
tat
deriv
tat
human
immunodefici
viru
hiv
artifici
sequenc
present
organ
polylysin
dnacondens
sequenc
defin
modul
part
protein
import
defin
order
final
construct
demonstr
boekl
cowork
use
melittin
conjug
polyethylenimin
pei
depend
side
linkag
cor
nterminu
lytic
activ
could
chang
modul
need
determin
posit
correct
function
produc
protein
gene
drug
deliveri
import
know
origin
domain
choos
suitabl
express
system
product
instanc
modul
natur
carri
posttransl
modif
essenti
biolog
function
express
system
chosen
abl
reproduc
crucial
modif
main
biolog
product
system
protein
drug
describ
escherichia
coli
wide
use
prokaryot
organ
express
recombin
protein
use
host
rel
simpl
inexpens
ad
advantag
includ
short
duplic
time
growth
high
cell
densiti
eas
cultiv
high
yield
recombin
product
howev
sinc
lack
fundament
prerequisit
effici
secret
recombin
protein
manufactur
e
coli
system
mainli
produc
inclus
bodi
moreov
posttranscript
modif
achiev
system
mani
exampl
protein
gene
deliveri
produc
e
coli
probe
effici
like
e
coli
yeast
grown
cheapli
rapidli
amen
highcelldens
ferment
besid
possess
complex
posttransl
modif
pathway
offer
advantag
neither
pyrogen
pathogen
abl
secret
effici
speci
establish
industri
product
procedur
saccharomyc
cerevisia
kluyveromyc
lacti
pichia
pastori
hansenulapolymorpha
cerevisia
best
genet
character
eukaryot
organ
among
still
preval
yeast
speci
pharmaceut
product
process
spite
physiolog
advantag
properti
nativ
high
express
secret
capac
employ
yeast
case
howev
might
reach
limit
particularli
pharmacolog
activ
product
impair
glycosyl
pattern
case
either
postsynthet
chemic
modif
consid
employ
highli
develop
organ
exampl
nanoparticl
produc
yeast
vlp
anim
cell
express
system
show
highest
similar
human
cell
regard
pattern
capac
posttransl
modif
codon
bia
howev
cultur
complic
costlier
usual
yield
lower
product
titer
among
known
system
insect
cell
infect
baculoviru
vector
reach
popular
sinc
consid
stressresist
easier
handl
product
compar
mammalian
system
thu
frequent
employ
highthroughput
protein
express
commerci
applic
scaleup
relat
question
solv
prefer
appli
pharmaceut
product
process
mammalian
system
like
chines
hamster
ovari
cho
cell
babi
hamster
kidney
bhk
cell
system
genet
stabl
easier
transform
handl
scaleup
process
grow
faster
adher
submerg
cultur
similar
human
cell
consist
complet
spectrum
modif
case
mammalian
cell
system
choic
prepar
correctli
modifi
protein
peptid
complex
uniqu
complex
molecul
regard
chemic
physic
properti
produc
synthet
solidphas
method
technolog
use
avoid
problem
relat
biolog
product
gener
advantag
synthet
peptid
stabl
compound
solidphas
chemistri
produc
highli
standard
peptid
crucial
polyc
compon
provid
natur
polyc
thu
minim
toxic
howev
disadvantag
relat
synthet
peptid
report
difficulti
synthes
long
wellfold
oligopeptid
peptid
multipl
cystein
methionin
arginin
tryptophan
residu
due
technic
limit
product
cost
work
protein
nanoparticl
import
character
physic
function
order
understand
behavior
size
charg
proteincargo
particl
crucial
properti
influenc
rate
diffus
bind
polyanion
compon
connect
tissu
transvers
anatom
barrier
bind
serum
protein
attach
cell
mechan
endocytosi
among
factor
stabil
physiolog
salt
solut
key
issu
vivo
deliveri
salt
found
everywher
bodi
mix
multival
polyc
dna
result
electrostat
bind
molecul
charg
neutral
dna
particl
format
name
conjug
charg
neutral
easili
seen
retard
gel
assay
particl
format
dynam
light
scatter
dl
dl
good
method
see
particl
format
quantifi
rel
number
particl
differ
size
visual
particl
mani
group
use
transmiss
electron
microscopi
tem
good
result
other
use
fluid
particl
imag
analyz
fpia
photograph
individu
particl
physiolog
solut
net
charg
proteincargo
particl
import
variabl
gener
optim
gene
deliveri
cell
line
requir
net
posit
charg
state
previous
determin
empir
one
best
techniqu
determin
net
charg
calcul
zeta
potenti
measur
electrophoret
mobil
particl
despit
fact
physic
character
key
element
understand
test
function
pharmacokinet
gene
drug
import
part
develop
process
initi
test
done
use
cell
line
vitro
experi
use
report
gene
rna
drug
quantifi
percentag
transfect
cell
druginduc
chang
valuabl
tool
evalu
nanoparticl
perform
nuclear
cytoplasm
deliveri
respect
addit
vitro
experi
may
design
select
candid
vivo
experi
group
possibl
therapi
vector
quantit
kinet
particl
bind
molecular
basi
particl
interact
target
cell
membran
effici
particl
intern
endosom
escap
poorli
understood
interact
particl
plasma
membran
prior
protein
intern
either
unspecif
specif
untarget
deliveri
normal
consequ
electrostat
interact
anion
ligand
cell
surfac
cation
compon
vehicl
hand
target
deliveri
specif
membran
molecul
sophist
approach
aim
improv
cell
specif
effici
direct
molecul
express
overexpress
particular
cell
type
initi
intern
endocytosi
target
moieti
includ
mani
type
molecul
discuss
afterward
intern
particl
mechan
kinet
well
known
studi
nanoparticl
deliveri
focu
aspect
sever
endocyt
pathway
initi
differ
ligand
enhanc
deliveri
addit
chloroquin
synthet
molecul
use
primarili
prophylaxi
treatment
malaria
disrupt
endosom
accept
paramet
demonstr
endosom
local
particl
endosom
escap
area
intens
investig
poorli
understood
import
practic
point
note
reagent
use
toxic
enhanc
step
anion
fusogen
peptid
use
peptid
fuse
membran
acidicdepend
manner
caus
disrupt
gene
deliveri
approach
transloc
dna
express
plasmid
cell
nucleu
involv
activ
energydepend
process
nuclear
pore
complex
directli
inject
dna
cytosol
usual
alway
poorli
transfer
nucleu
use
protein
carri
cation
nuclearloc
sequenc
larg
antigen
wide
use
overcom
step
iv
natur
selfassembl
protein
nanoparticl
vlp
ideal
drug
deliveri
gene
therapi
vehicl
must
accomplish
desir
featur
appropri
packag
size
cargo
target
cellspecif
safe
effici
cargo
deliveri
protect
immun
recognit
capabl
escap
immun
recognit
moreov
vehicl
must
avoid
inflammatori
toxic
rapid
clearanc
context
viral
vector
exploit
one
vehicl
choic
virus
nanos
nm
supramolecular
nucleoproteinbas
entiti
cover
lipid
bilay
envelopednonenvelop
virus
satisfi
rel
simpl
structur
outstand
properti
function
relev
drug
gene
deliveri
virus
abl
recogn
interact
specif
cell
receptormedi
bind
intern
escap
endosom
uncoat
releas
nucleic
acid
differ
cellular
compart
also
capabl
transcrib
translat
viral
protein
selfassembl
new
infecti
viru
particl
exit
host
cell
despit
relev
properti
viral
vector
rise
vehicl
drug
gene
deliveri
cation
liposom
therapeut
use
present
limit
risk
complex
product
limit
packag
capac
insert
mutagenesi
gene
inactiv
low
probabl
integr
reduc
efficaci
repeat
administr
reduc
express
overtim
unfavor
immunolog
recognit
strong
immun
respons
vehicl
transgen
inflammatori
toxic
rapid
clearanc
context
viru
capsid
vlp
produc
recombin
capsid
protein
lack
viral
genom
notic
emerg
safer
altern
viral
vector
structur
protein
selfassembl
nanovehicl
vlp
classic
describ
selfassembl
nonrepl
nonpathogen
highli
organ
supramolecular
multiprotein
nanoparticl
coat
rang
nm
form
minim
spontan
selfassembl
one
viral
structur
capsid
protein
describ
selfassembl
process
structur
viral
protein
vlp
format
involv
spontan
assembl
favor
experiment
condit
requir
scaffold
protein
catalyst
therefor
vlp
consid
protein
coat
shell
box
lack
viral
genom
still
conserv
structur
morpholog
properti
virus
properti
cellular
tropism
uptak
intracellular
traffick
membran
transloc
transfer
nucleic
acid
molecul
across
cytoplasm
endosom
nuclear
membran
import
drug
deliveri
gene
therapi
usual
degre
similar
vlp
virus
depend
number
protein
incorpor
construct
sinc
first
descript
viral
dna
packag
mous
polyomaviru
mpyv
vlp
transduct
vitro
vlp
differ
virus
papillomavirus
hepat
b
c
e
virus
polyomavirus
vlp
offer
structur
dynam
characterist
featur
function
make
appeal
bionanomateri
exploit
biomedicin
arena
drug
gene
deliveri
vehicl
discuss
detail
afterward
one
hand
viral
coat
protein
abil
spontan
selfassembl
ensur
format
highli
organ
regular
repetit
structur
stabl
low
morpholog
polydispers
particl
provid
use
properti
use
scaffold
bioimag
synthesi
bionanomateri
nanocarri
drug
gene
therapi
addit
homogen
particl
size
composit
desir
product
factor
develop
therapeut
molecul
overexpress
structur
viral
protein
conveni
express
system
render
recombin
protein
capabl
fold
assembl
discret
organ
nanoparticl
defin
size
correspond
natur
capsid
geometri
moreov
even
though
vlp
structur
stabl
particl
biochem
structur
studi
observ
viral
capsid
bacteriophag
may
show
structur
dynam
properti
vari
shape
size
rearrang
coat
protein
respons
differ
factor
ph
hand
vlp
consid
biolog
safe
nanostructur
sinc
infecti
lack
viral
genom
replic
repres
safer
altern
viral
vector
howev
elicit
immun
inflammatori
respons
especi
repeat
administr
need
also
note
use
vaccin
vlp
could
show
excel
adjuv
properti
major
vlp
stimul
strong
cellular
humor
immun
respons
direct
immunogen
suggest
recombin
vlp
deriv
infect
insect
cell
baculoviru
even
deriv
prokaryot
system
could
contamin
differ
residu
compon
host
cell
contribut
impur
adjuv
properti
one
interest
properti
vlp
coat
viral
protein
present
enorm
elast
adapt
modifi
chemic
andor
protein
genet
engin
incorpor
multipl
direct
function
order
address
biomed
applic
drug
deliveri
gene
therapi
recent
review
chemic
andor
genet
modifi
vlp
includ
cpmv
ccmv
bacteriophag
virusbas
nanoparticl
could
maintain
structur
integr
improv
physic
stabil
moreov
modif
could
also
confer
desir
celltarget
properti
nanovehicl
vlp
success
engin
spatial
precis
incorpor
attach
genet
display
surfac
target
tissuespecif
ligand
epiderm
growth
factor
egfr
antibodi
molecul
oligonucleotid
peptid
gold
metal
target
protein
carbohydr
polym
fluorophor
quantum
dot
drug
small
molecul
moreov
one
potenti
benefit
modif
specif
geometr
rearrang
confer
precis
recognit
pattern
furthermor
access
materi
carri
within
particl
abil
inclus
separ
nucleic
acid
small
molecul
unusu
cargo
appropri
charg
anoth
outstand
featur
key
advantag
vlp
also
made
excel
vessel
gene
drug
deliveri
describ
vlp
use
empti
nanocarri
transport
molecul
chemic
attach
surfac
load
ex
vivo
therapeut
small
molecul
drug
dna
mrna
sirna
oligonucleotid
quantum
dot
magnet
nanoparticl
protein
vlp
differ
papillomaviru
polyomaviru
wide
character
use
direct
deliveri
biomed
applic
osmot
shock
vitro
selfassembl
vlp
subunit
presenc
cargo
two
main
strategi
use
packag
nucleic
acid
small
molecul
taken
account
attach
cargo
vlp
surfac
occur
besid
divers
natur
tropism
includ
liver
hepat
b
vlp
spleen
papillomaviru
polyomaviru
vlp
antigenpres
cell
certain
papillomaviru
vlp
glial
cell
human
polyomaviru
jc
jcv
vlp
among
other
one
key
advantag
offer
vlp
provid
wide
spectrum
specif
target
distribut
profil
depend
direct
applic
although
vlp
characterist
receptor
entri
pathway
intracellular
traffick
demonstr
tropism
vlp
could
custom
modifi
residu
identifi
ligand
cellular
receptor
vlp
surfac
even
vari
deliveri
rout
anoth
key
advantag
vlp
easili
produc
use
wide
rang
host
express
system
condit
past
year
increas
need
improv
optim
effici
largescal
product
system
process
control
monitor
upand
downstream
process
product
vlp
usual
involv
transfect
cell
host
express
system
choic
plasmid
encod
one
viral
structur
protein
rigor
purif
remov
immunogen
cellular
contamin
qualiti
control
produc
vlp
encapsul
cargo
ex
vivo
administr
frequent
conveni
express
system
adapt
largescal
process
yeast
cell
bacteria
green
plant
infect
modifi
virus
cellfre
system
prepar
largescal
manufactur
vlp
host
review
pattenden
et
al
classifi
two
main
method
bioprocess
vivo
vitro
system
addit
capabl
vitro
dissoci
reassoci
vlp
contribut
applic
easi
accur
purif
method
viral
vector
furthermor
depend
express
system
result
vlp
might
significantli
differ
even
though
express
viral
protein
thu
broad
spectrum
vlp
could
custom
depend
vlp
type
number
protein
need
vlp
assembl
target
final
applic
describ
vlp
great
potenti
nanocarri
drug
gene
deliveri
time
although
increas
flow
develop
area
vehicl
also
present
limit
address
taken
account
residu
cellular
compon
variabl
yield
function
vlp
disassemblyreassembl
process
immunostimul
unsuit
repeat
administr
toler
transgen
ineffect
therapeut
molecul
load
low
transfect
rate
protein
nanoparticl
engin
drug
deliveri
gene
therapi
due
versatil
nanoparticul
structur
morpholog
nonrepl
noninfect
natur
combin
natur
immunogen
properti
eas
product
vlp
princip
emerg
excel
altern
tool
attenu
virus
vaccin
ebola
viru
although
vlpbase
vaccin
primarili
develop
use
correspond
viru
last
decad
genet
engin
chemic
modif
appli
order
gener
chimer
vlp
thu
one
hand
commonli
short
heterolog
peptid
epitop
full
protein
unabl
form
vlp
unsaf
vaccin
present
surfaceexpos
loop
fuse
cexpos
termini
structur
viral
capsid
protein
vlp
differ
hpv
hbv
parvoviru
chimer
polyoma
vlp
engin
test
differ
applic
includ
vaccin
viral
bacteri
diseas
virusinduc
tumor
recent
immunotherapi
nonvir
cancer
hand
chemic
bioconjug
coval
coupl
protein
epitop
small
molecul
lysin
cystein
tyrosin
residu
vlp
surfac
appli
viral
cancer
vaccin
chackerian
et
al
demonstr
effici
induct
protect
autoantibodi
use
selfantigen
conjug
hpv
vlp
import
point
vlp
also
engin
incorpor
heterolog
cellspecif
ligand
cell
receptor
thu
alter
cellular
tropism
great
convert
flexibl
vlp
modifi
chemic
andor
genet
high
stabil
natur
divers
tropism
nanocontain
properti
abil
enter
cell
incorpor
bind
deliv
nucleic
acid
small
molecul
posit
vlp
appeal
entiti
vaccin
applic
also
broad
spectrum
divers
emerg
applic
nanomedicin
nanotechnolog
immunotherapi
cancer
gene
therapi
deliveri
therapeut
gene
specif
cell
target
deliveri
drug
small
molecul
use
vlp
nanocarri
et
al
although
commerci
vlp
vector
gene
therapi
sinc
initi
work
uncoat
polyoma
pseudoviru
mous
embryo
cell
gene
deliveri
vector
establish
viral
dna
packag
mpyv
vlp
transduct
vitro
differ
vlp
hbv
hepat
e
viru
hpv
polyomaviru
nanoparticl
modifi
toward
specif
deliveri
therapeut
gene
protein
differ
target
cell
organ
tissu
vitro
vivo
system
inject
oral
administr
exampl
recombin
polyomaviru
vlp
encapsul
vitro
exogen
dna
deliv
cell
surfac
sialic
acid
residu
human
brain
cell
fetal
kidney
epitheli
cell
furthermor
vlp
recent
emerg
novel
nanocarri
nanocontain
store
unnatur
cargo
deliv
modifi
oligonucleotid
synthet
small
interf
rna
plasmid
express
short
hairpin
rna
therapi
downregul
gene
express
context
chou
et
al
recent
describ
use
jcv
vlp
effici
vector
deliv
rnai
vitro
use
murin
macrophag
raw
cell
vivo
use
balbc
mice
silenc
cytokin
gene
without
signific
cytotox
system
lupu
erythematosu
gene
therapi
one
key
aspect
target
gene
drug
deliveri
cellspecif
deliveri
import
point
vlp
tunabl
nanoparticl
also
chemic
genet
engin
modifi
natur
cellular
tropism
order
diversifi
rang
therapeut
applic
target
gene
drug
deliveri
effect
approach
modifi
natur
cellular
tropism
includ
genet
engin
vlp
chimera
incorpor
heterolog
cellspecif
short
peptid
contain
recognit
site
target
cell
receptor
context
polyoma
papillomaviru
solv
atom
structur
major
structur
capsid
protein
extens
use
obtain
chimer
vlp
deliveri
vector
system
howev
approach
bioprocess
limit
low
product
level
consequ
vlp
modif
alter
size
properti
vlp
could
affect
structur
interact
conform
vlp
assembl
disassembl
packag
low
transduct
effici
chemic
bioconjug
purifi
vlp
epitopecontain
peptid
wide
rang
small
molecul
confer
cellspecif
target
transferrin
folic
acid
target
molecul
exampl
cmpv
vlp
success
conjug
tfn
use
click
chemistri
nhsesterderivat
folic
acid
demonstr
intern
hela
cell
kb
cell
respect
highthroughput
librari
direct
evolut
method
ration
approach
recent
use
engin
viral
vector
desir
tropism
properti
pseudotyp
consist
replac
envelop
protein
one
viru
speci
envelop
protein
anoth
viru
speci
modif
deliveri
rout
vlp
shown
level
express
bgalactosidas
heart
lung
kidney
spleen
liver
brain
differ
depend
deliveri
rout
polyomaviru
vlp
great
access
reactiv
show
vlp
well
abil
serv
nanocarri
made
suitabl
exploit
gene
therapi
also
appli
target
drug
deliveri
genet
modif
andor
chemic
function
expos
amino
acid
residu
capsid
surfac
order
attach
small
molecul
marker
bioactiv
molecul
one
common
approach
appli
target
drug
deliveri
exampl
canin
parvoviru
cpv
vlp
produc
baculoviru
express
system
exhibit
natur
tropism
transferrin
receptor
tfr
chemic
modifi
access
lysin
capsid
surfac
fluoresc
dye
molecul
deliv
tumor
cell
derivat
cpvvlp
interfer
bind
intern
tumor
cell
one
limit
vlp
gene
therapi
low
effici
gene
transduct
due
ineffici
dna
packag
howev
recent
studi
present
novel
vivo
dna
packag
jcv
vlp
e
coli
effect
reduc
human
colon
carcinoma
volum
nude
mous
model
studi
exogen
plasmid
dna
transform
jcv
express
e
coli
packag
second
plasmid
occur
simultan
vivo
assembl
jcv
vlp
even
though
still
clear
plasmid
dna
molecul
encapsid
vlp
author
show
gene
transduct
effici
vivo
packag
system
contrast
gene
transduct
effici
achiev
vitro
osmot
shock
system
addit
administr
exogen
protein
may
induc
immun
system
respons
reduc
therapi
effect
caus
undesir
secondari
effect
albeit
immunolog
respons
protein
nanoparticl
modul
spontan
protein
selfassembl
form
order
oligom
common
event
biolog
prove
advantag
term
genomes
minim
format
larg
structur
stabil
complex
inclus
function
featur
wide
document
cellular
oligom
protein
well
viral
capsid
stabil
sever
weak
noncoval
interact
hydrophob
interact
electrostat
energi
van
der
waal
forc
interact
result
complex
quaternari
structur
describ
three
symmetri
point
group
name
cyclic
cn
dihedr
dm
cubic
develop
comput
techniqu
predict
proteinprotein
interact
use
solv
protein
structur
make
possibl
predict
andor
strengthen
experiment
data
perform
silico
approach
furthermor
use
open
possibl
design
protein
display
specif
biolog
function
also
interest
intermolecular
interact
obtain
increas
multival
result
complex
moreov
consid
whole
protein
selfassembl
smart
nanoparticl
oligopeptid
also
capabl
form
organ
structur
mani
applic
possibl
due
enorm
quantiti
differ
combin
featur
exploit
peptid
furthermor
proteinprotein
interact
uniqu
paramet
involv
particl
format
nucleic
acidpeptid
interact
salt
concentr
order
mix
ratio
nucleic
acid
protein
also
strongli
influenc
condens
process
due
natur
tendenc
selfassembl
form
highli
order
structur
virus
provid
wide
varieti
scaffold
protein
use
genedrug
carrier
among
vlp
review
previou
section
howev
simpl
bacteri
protein
also
util
carrier
gene
deliveri
exampl
heat
shock
protein
hsp
hyperthermophil
archeaon
methanococcu
jannaschii
assembl
small
structur
subunit
octahedr
symmetri
nm
structur
stabl
high
temperatur
c
wide
rang
ph
residu
modif
allow
elicit
specif
attach
small
molecul
bacteria
bacteri
microcompart
bmc
intracellular
organel
consist
enzym
encapsul
within
polyhedr
proteinonli
shell
somewhat
similar
viral
capsid
describ
bmc
compos
thousand
copi
repeat
protein
speci
includ
one
enzym
involv
specif
metabol
pathway
size
around
nm
cross
section
gener
role
bmc
confin
toxic
volatil
metabol
intermedi
allow
enzym
substrat
product
cofactor
pass
first
describ
bmc
carboxysom
isol
earli
found
contain
co
fix
ribulos
bisphosph
carboxylaseoxygenas
rubisco
carbon
anhydras
enzym
carboxysom
function
enhanc
autotroph
co
fixat
low
co
level
bmc
later
identifi
cyanobacteria
chemoautotroph
bacteria
among
bmc
protein
later
found
encod
propanediol
util
operon
pdu
heterotroph
salmonella
operon
metabol
ethanolamin
eut
enter
bacteri
speci
includ
salmonella
escherichia
salmonella
enterica
form
polyhedr
organel
growth
sole
carbon
energi
sourc
growth
carbon
sourc
pdu
organel
function
minim
harm
effect
toxic
intermedi
degrad
propionaldehyd
studi
shown
polyhedr
organel
involv
ethanolamin
util
eut
enterica
function
eut
microcompart
metabol
ethanolamin
without
allow
releas
acetaldehyd
cytosol
therefor
minim
potenti
toxic
effect
excess
aldehyd
bacteri
cytosol
also
prevent
volatil
acetaldehyd
diffus
across
cell
membran
far
protein
contain
bmc
domain
identifi
cover
least
differ
bacteri
phyla
typic
bmc
protein
consist
approxim
amino
acid
alphabeta
fold
pattern
individu
bmc
protein
selfassembl
form
hexam
assembl
side
side
form
flat
facet
shell
format
icosahedr
close
shell
flat
layer
elucid
part
structur
studi
carboxysom
bmc
protein
assembl
form
pentam
locat
form
vertic
icosahedr
shell
mechan
direct
enzym
encapsul
within
proteinbas
bmc
studi
last
year
describ
carboxysom
protein
ccmm
use
scaffold
form
interact
shell
protein
enzym
ccmm
ctermin
region
homolog
small
subunit
rubisco
studi
reveal
pdu
shell
selfassembl
without
need
interior
enzym
carboxysom
selfassembl
vivo
rubisco
delet
regard
properti
encapsul
enzym
pdu
bmc
intern
enzym
encapsul
specif
ntermin
target
sequenc
line
sutter
colleagu
describ
conserv
ctermin
amino
acid
sequenc
mediat
physic
interact
irondepend
peroxidas
dyp
protein
close
relat
ferritin
flp
specif
type
bmc
encapsulin
anoth
exampl
icosahedr
enzym
complex
lumazin
synthas
aal
bacillu
subtili
aquifex
aeolicu
engin
encapsul
target
molecul
mean
charg
complementar
also
modifi
give
differ
characterist
assembl
structur
moreov
enzymat
subunit
like
pyruv
dehydrogenas
bacillu
stearotermophilu
modifi
use
gene
deliveri
peptid
natur
form
dodecahedron
subunit
nm
diamet
allow
modif
druglik
accommod
assemblingdisassembl
structur
modul
chang
oper
ph
experiment
environ
nanoparticl
also
function
antigen
vaccin
develop
accord
result
specif
target
sequenc
could
use
biotechnolog
applic
packag
protein
insid
stabl
selfassembl
icosahedr
shell
bmc
offer
appeal
opportun
manipul
laboratori
nanocag
fill
therapeut
molecul
simplic
system
make
attract
engin
studi
design
mimick
natur
new
applic
biotechnolog
provid
new
intrigu
platform
microbi
origin
drug
deliveri
bovin
serum
albumin
bsa
abl
form
microspher
sonochem
treatment
aqueou
medium
chemic
effect
ultrasound
radiat
coupl
anticanc
drug
taxol
paclitaxel
led
assembl
spheric
carrier
averag
diamet
nm
bsa
particl
result
ss
bond
due
ho
radic
format
abl
releas
encapsul
taxol
cancer
tissu
best
result
compar
mere
taxol
treatment
drug
breast
cancer
treatment
commerci
avail
also
littl
cation
peptid
lead
selfassembl
particl
among
other
argininerich
cation
peptid
wide
known
good
tool
gene
deliveri
exampl
purifi
gfp
solut
describ
form
nanodisk
particl
nm
diamet
structur
prove
induc
arg
tail
abl
bind
condens
dna
nanodisk
also
abl
deliv
dna
toward
nucleu
report
gene
express
hand
express
recombin
protein
physiolog
rate
caus
bad
function
cellular
qualiti
control
system
lead
selforgan
pseudospher
protein
aggreg
known
inclus
bodi
mechan
stabl
nanoparticl
rang
nm
diamet
consid
long
time
undesir
bioproduct
recent
becam
clearer
suitabl
medic
approach
util
scaffold
surfac
promot
cellular
prolifer
one
difficult
goal
foreign
gene
deliveri
reach
nucleu
approach
overpass
obstacl
fuse
nl
nonessenti
posit
dnabind
protein
type
modif
describ
tetracyclin
repressor
protein
tetr
fuse
nl
tetrnl
affin
specif
teto
dna
sequenc
exploit
form
spontan
proteindna
complex
allow
enhanc
dna
transport
nucleu
subsequ
express
foreign
gene
combin
two
peculiar
characterist
fusion
compon
still
tremend
gap
progress
made
proteinbas
nanoparticl
research
drug
deliveri
clinic
realiti
hundr
public
basic
research
describ
combin
two
function
element
singl
protein
nanoparticl
deliveri
carri
drug
enhanc
agent
act
improv
critic
step
drug
deliveri
process
increas
system
stabil
tissu
specif
favor
intern
endosom
escap
entri
nucleu
transport
therapeut
materi
bbb
vitro
vivo
studi
besid
human
recombin
therapeut
protein
current
market
function
segment
also
fusion
protein
approv
clinic
use
incorpor
antibodi
fragment
ligand
enhanc
cell
specif
sadli
gene
therapi
trial
far
use
full
protein
carrier
vivo
rather
peptidefunction
vehicl
bottleneck
gap
research
clinic
applic
us
fdaeuropean
medicin
agenc
emea
approv
human
protein
avoid
risk
immun
respons
could
affect
effect
nanoparticl
also
challeng
patient
health
anoth
critic
factor
administr
rout
protein
degrad
arriv
target
problem
could
solv
minim
use
protein
disom
pegyl
design
protect
group
labil
site
despit
current
situat
mention
mani
good
exampl
multifunct
modular
protein
carri
therapeut
materi
improv
prognosi
vivo
anim
model
differ
diseas
exampl
review
along
protein
nanoparticl
current
market
clinic
trial
albumin
natur
protein
transport
hydrophob
molecul
throughout
plasma
approv
fda
revers
bind
waterinsolubl
anticanc
agent
case
albuminbound
nab
paclitaxel
abraxan
albuminnab
technologybas
drug
use
patient
metastat
breast
cancer
fail
combin
therapi
first
protein
nanoparticl
approv
fda
albumin
potenti
paclitaxel
concentr
within
tumor
increas
paclytaxel
endotheli
transcytosi
caveola
format
also
contribut
fact
tumor
secret
albuminbind
protein
sparc
also
call
attract
keep
albuminbound
nutrient
insid
tumor
cell
albuminpaclitaxel
complex
formal
consid
nanoparticl
unit
state
due
averag
size
nm
europ
apart
whole
recombin
therapeut
protein
current
commerci
also
exampl
vehicl
form
chimer
protein
target
ligand
alreadi
market
denileukin
diftitox
ontak
fusion
diphtheria
toxin
catalyt
transloc
domain
lethal
effect
gain
cell
specif
treatment
persist
recurr
tcell
lymphoma
belatacept
fusion
protein
form
cytotox
tlymphocyteassoci
antigen
join
immunoglobulin
fc
fragment
fusion
protein
develop
bristolmierssquibb
etanercept
enbrel
fusion
tumor
necrosi
factor
receptor
tnfr
bind
inhibit
specif
tnf
activ
immun
globulin
fc
prevent
inflamm
mediat
tnf
autoimmun
diseas
like
arthriti
psoriasi
hand
fusion
protein
includ
antihuman
epiderm
growth
factor
receptor
monoclon
antibodi
bind
tumor
cell
surfac
among
socal
trastuzumab
commerci
herceptin
roch
associ
antimitot
drug
aim
improv
treatment
breast
cancer
final
vlp
empti
viral
entiti
form
selfassembl
viral
capsid
protein
truli
protein
nanoparticl
architecton
speak
current
use
clinic
practic
hbsag
recombin
protein
hbv
express
yeast
capsid
recombin
protein
hpv
type
administ
current
vaccin
tend
form
spontan
vlp
elicit
b
immun
respons
recent
preclin
clinic
trial
test
secur
efficaci
vlp
vaccin
chikungunya
season
influenza
viru
http
www
respect
influenza
vlp
vaccin
proven
provid
complet
protect
flu
pandem
within
record
prepar
time
compar
month
tradit
vaccin
use
vlp
deliveri
system
drug
nucleic
acid
gene
therapi
still
investig
drug
protein
may
transform
pegyl
process
assist
overcom
potenti
problem
delay
adopt
protein
nanoparticl
clinic
use
coval
attach
peg
reduc
immunogen
antigen
hide
particl
immun
system
increas
circul
time
reduc
renal
clearanc
also
improv
water
solubl
hydrophob
particl
use
pegyl
approv
commerci
use
fda
emea
exampl
pegyl
protein
product
adagen
pegbovin
adenosin
deaminas
first
pegyl
protein
approv
fda
pegasi
peginterferon
alpha
oncaspar
peglasparaginas
major
protein
nanoparticl
studi
clinic
trial
http
clinicaltriasgov
fusion
protein
compos
therapeut
proteinpeptid
target
cellspecif
ligand
exampl
biolog
compound
compos
genet
fuse
human
solubl
tcell
receptor
direct
antigen
clinic
trial
evalu
whether
direct
activ
use
patient
tumor
site
overexpress
result
clinic
benefit
anoth
ligand
join
tumortarget
immunocytokin
constitut
singl
chain
fragment
variabl
scfv
direct
edb
domain
fibronectin
one
import
marker
neoangiogenesi
phase
iii
studi
patient
solid
tumor
renal
cell
carcinoma
rcc
also
fuse
tnfa
intent
target
tnfa
directli
tumor
tissu
result
high
sustain
intralesion
bioactiv
tnfa
concentr
clinic
trial
use
isol
inferior
limb
perfus
ilp
standard
treatment
melphalan
mgl
limb
volum
subject
affect
stage
iiiiv
limb
melanoma
ngrhtnf
anoth
bifunct
protein
combin
tumorhom
peptid
ngr
select
bind
amino
peptidas
highli
express
tumor
blood
vessel
thu
affect
tumor
vascular
permeabl
htnf
direct
anticanc
activ
ngrhtnf
undergo
clinic
trial
singl
agent
treat
differ
cancer
well
combin
chemotherapi
agent
anoth
strategi
direct
therapeut
protein
target
cell
fusion
growth
factor
receptor
ligand
exampl
recombin
chimer
protein
compos
egfr
bind
ligand
tgfa
genet
engin
form
pseudomona
exotoxin
treat
recurr
grade
iv
malign
brain
tumor
mani
clinic
trial
base
therapeut
protein
fuse
target
antibodi
case
drug
stimul
immun
system
stop
cancer
cell
grow
combin
biolog
therapi
bevacizumab
alreadi
approv
monoclon
antibodi
locat
tumor
cell
kill
specif
way
also
mani
put
protein
drug
cancer
includ
antibodi
antiintegrin
eg
cilengitid
sometim
combin
classic
therapi
recent
develop
tool
nanobodi
singl
domain
antibodi
sever
advantag
small
size
kda
lower
possibl
trigger
immun
respons
safeti
clinic
trial
easi
join
differ
kind
compound
featur
make
nanobodi
compet
drug
differ
diseas
test
vivo
bifunct
protein
associ
prodrug
effici
mice
cancer
xenograft
even
though
cpp
use
tool
deliv
drug
gene
therapi
see
chapter
peptid
nanoparticl
oligonucleotid
deliveri
lehto
et
al
volum
toxic
endosom
entrap
slow
inclus
system
deliveri
clinic
trial
nevertheless
exampl
use
prevent
undesir
cell
prolifer
coronari
arteri
bypass
graft
case
cpp
rahxr
ahxbpmo
conjug
target
human
cmyc
appli
ex
vivo
trial
phase
ii
complet
anoth
case
psorban
product
patent
treatment
psoriasi
base
cyclosporinepolyarginin
conjug
local
applic
circumv
specif
problem
intraven
iv
applic
clinic
trial
phase
iii
yet
market
final
pkcd
inhibitor
peptid
conjug
tat
function
intraven
drug
treatment
acut
myocardi
infarct
current
phase
clinic
trial
kai
pharmaceut
mani
protein
often
organ
nanoparticl
associ
drug
therapeut
protein
peptid
nucleic
acid
increas
therapeut
efficaci
cargo
alon
treatment
variou
diseas
prove
effect
anim
model
discuss
detail
section
relev
exampl
list
tabl
ii
nanoparticl
may
simpli
cpp
promot
nonspecif
intern
b
peptid
confer
cargo
specif
join
receptor
distinct
cell
type
includ
scfv
peptid
obtain
phage
display
c
mixtur
sinc
observ
sever
studi
cpp
reduc
ligand
specif
increas
nanoparticl
potenc
complex
multifunct
vehicl
includ
endosom
escap
peptid
enhanc
therapeut
potenc
complex
domain
allow
select
activ
certain
context
apart
case
list
tabl
ii
spectrum
addit
exampl
multidomain
protein
nanoparticl
test
vivo
wide
consider
proport
includ
cpp
mainli
tat
polyarginin
classic
tat
fusion
protein
transduc
disom
fusion
protein
activ
protein
cancer
cell
normal
cell
treatment
termin
periton
carcinomatosi
periton
lymphoma
preclin
model
result
signific
increas
life
span
higher
sixfold
full
recoveri
diseas
also
sever
studi
vivo
use
tatfus
therapeut
protein
proven
effect
treat
tumor
cerebr
ischemia
appli
intraperiton
ip
regard
polyarginin
kumar
colleagu
present
two
differ
model
bifunct
peptid
form
nine
arginin
specif
ligand
constitut
effect
sirna
vehicl
first
model
chimer
peptid
deriv
rabi
viru
glycoprotein
confer
neuron
specif
fuse
abl
transport
sirna
across
bbb
silenc
specif
gene
express
brain
appli
intraven
second
model
singlechain
antibodi
conjug
peptid
cellspecif
antivir
sirna
deliveri
human
mice
reconstitut
human
lymphocyt
hivinfect
human
mice
treatment
control
viral
replic
prevent
diseaseassoci
cell
loss
moreov
effect
suppress
viremia
infect
mice
exampl
polyarginin
tumor
model
fuse
tumorsuppressor
peptid
stop
tumor
growth
hepatocellular
carcinomabear
mice
appli
intraperiton
also
colesteryl
oligoarginin
carri
vegf
sirna
inhibit
tumor
growth
colon
adenocarcinoma
local
applic
anoth
bbbcross
peptid
abl
transport
nanoparticl
load
loperamid
gener
partner
fusion
peptid
confer
specif
instead
penetr
case
egfr
fab
fragment
associ
liposom
contain
anticanc
drug
increas
effici
anticanc
effect
egf
overexpress
xenograft
tumor
addit
cdoxorubicin
human
breast
xenograft
increas
efficaci
diminish
toxic
mani
conjug
therapeut
peptid
chimer
protein
toxin
anthrax
lethal
toxin
modifi
activ
methaloproteas
probe
effect
human
xenograft
tumor
melanoma
lung
colorect
cancer
anthrax
toxin
also
associ
antibodi
growth
factor
lethal
effect
specif
cancer
cell
specif
cytotox
desir
treat
tumor
might
deriv
tissu
factor
promot
clot
restrict
blood
suppli
tumor
vessel
fuse
peptid
provid
specif
like
vcam
antibodi
fibronectin
integrin
ligand
eventu
drug
activ
may
decreas
conjug
carrier
protein
although
entri
drug
favor
overal
balanc
activ
much
effici
hand
use
noncoval
bond
drug
carrier
could
avoid
interf
activ
drug
import
issu
preclin
studi
consid
clinic
trial
administr
rout
vivo
experi
protein
nanoparticl
administ
local
intraperiton
inject
avoid
system
spread
clearanc
vascular
system
way
similar
vitro
experi
fda
emea
hand
preferenti
approv
iv
oral
administr
rather
intraperiton
local
inject
except
access
tissu
anoth
relev
issu
number
activ
domain
includ
therapeut
protein
carrier
issu
seem
relev
function
construct
exampl
cpp
neutral
ligand
may
depend
cppligand
ratio
vehicl
also
observ
integrin
bind
power
rgdcontain
motiv
increas
number
rgd
domain
monom
maxim
four
moieti
anoth
exampl
tat
activ
empower
attach
molecul
form
tetram
betagalactosidas
multidomain
protein
carrier
allow
drug
entranc
select
target
cell
tailor
smart
select
mechan
instanc
cpp
neutral
polyanion
activ
enter
cell
releas
metalloproteas
lower
ph
situat
common
tumor
cppmorpholino
oligom
pmo
nanoparticl
also
shown
effect
treat
viral
infect
inhibit
viral
replic
demonstr
carrier
rahxr
administ
iv
anim
model
infect
picornavirus
ip
mice
infect
coronavirus
flavivirus
carrier
administ
also
ip
mice
infect
ebola
viru
furthermor
also
shown
studi
efficaci
treatment
depend
incorpor
argininerich
peptid
nanoparticl
good
exampl
cpp
improv
intern
therapeut
protein
case
insulin
instabl
low
absorpt
digest
tract
insulin
prevent
oral
administr
even
though
would
conveni
daili
administr
drug
recent
studi
noncoval
conjug
insulin
differ
cpp
enhanc
absorpt
without
toxic
intestin
effect
lpenetratin
effici
insulin
carrier
among
protein
nanoparticl
test
vivo
worth
make
special
mention
trojan
hors
gener
pardridg
laboratori
cross
bbb
strategi
fuse
within
chimer
peptid
therapeut
protein
reach
cn
monoclon
antibodi
human
insulin
receptor
hirmab
trojan
hors
potent
human
primat
proven
effect
transport
bglucuronidas
aliduronidas
gdnf
abeta
amyloid
peptid
paroxonas
etc
potenti
benefit
diseas
like
mucopolysaccharidosi
type
vii
hurler
syndrom
parkinson
alzheim
organophosph
toxic
respect
also
promis
result
protein
nanoparticl
test
carrier
gene
therapi
vivo
exampl
list
tabl
ii
regard
use
modular
protein
gener
insert
mutagenesi
bgalactosidas
condens
sod
gene
abl
protect
neuron
ischem
injuri
bifunct
galactosyl
polylysin
abl
conjug
plasmid
dna
differenti
promot
express
hepatocyt
display
asialoglycoprotein
receptor
suicid
multidomain
protein
particl
form
herp
simplex
viru
thymidin
kinas
hsvtk
conjug
transferrin
tf
biotinstreptavidin
bridg
administ
iv
massiv
metastas
nude
mice
abl
reduc
tumor
size
increas
mous
surviv
chapter
protein
peptid
envis
potent
biotechnolog
tool
develop
new
biocompat
biolog
entiti
use
therapeut
agent
nanovehicl
deliveri
associ
drug
protein
nanostructur
form
complex
highord
entiti
vlp
result
appropri
cage
intern
therapeut
molecul
addit
design
modular
protein
display
select
function
possibl
use
silico
approxim
feasibl
recombin
protein
product
approach
demonstr
versatil
molecul
gener
novel
deliveri
nanovehicl
open
possibl
new
function
combin
enhanc
specif
interact
target
tissu
tunabl
specif
deliveri
drug
nucleic
acid
protein
one
main
properti
make
multifunct
protein
appeal
ration
deliveri
vehicl
presenc
market
complex
entiti
start
approv
insulin
treatment
diabet
increas
past
year
tendenc
expect
continu
fact
product
clinic
trial
probabl
end
approv
explor
preclin
experi
might
enter
clinic
trial
